Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib

Bibliography

• Xie Y, Davies SM, Xiang Y, Trends in leukemia incidence and survival in the United States (1973 – 1998). Cancer 2003;97(9):2229-35
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Young NS, Gatterman N, Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2002;136-61
   PubMedGoogle Scholar
• Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109(8):1536-42
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112(1):45-52
   PubMed Web of Science ®Google Scholar
• Mattison RJ, Ostler KR, Locke FL, Godley LA. Implications of FLT3 mutations in the therapy of acute myeloid leukemia. Rev Recent Clin Trials 2007;2(2):135-41
   PubMedGoogle Scholar
• Pinheiro RF, de Sa Moreira E, Silva MR, FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia. Cancer Genet Cytogenet 2008;183(2):89-93
   PubMed Web of Science ®Google Scholar
• Padua RA, Carter G, Hughes D, RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia 1988;2(8):503-10
   PubMed Web of Science ®Google Scholar
• Ehmann F, Horn S, Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations. Leuk Lymphoma 2006;47(7):1387-91
   PubMed Web of Science ®Google Scholar
• Recher C, Dos Santos C, mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 2005;4(11):1540-9
   PubMed Web of Science ®Google Scholar
• Faderl S, Pal A, Bornmann W, Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Res 2009;69(9):3910-7
   PubMed Web of Science ®Google Scholar
• Dickson DJ, Shami PJ. Angiogenesis in acute and chronic leukemias. Leuk Lymphoma 2001;42(5):847-53
   PubMed Web of Science ®Google Scholar
• Lancet JE, Karp JE. Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev 2003;17(3):123-9
   PubMed Web of Science ®Google Scholar
• Saglio G, Serra A, Novarino A, N-ras mutations in myeloid leukemias. Tumori 1989;75(4):337-40
   PubMed Web of Science ®Google Scholar
• Auewarakul CU, Lauhakirti D, Tocharoentanaphol C. Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia. Eur J Haematol 2006;77(1):51-6
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach T, Schoch C, Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006;107(10):3847-53
   PubMed Web of Science ®Google Scholar
• Niimi H, Harada H, Harada Y, Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia 2006;20(4):635-44
   PubMed Web of Science ®Google Scholar
• Paquette RL, Landaw EM, Pierre RV, N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993;82(2):590-9
   PubMed Web of Science ®Google Scholar
• Neubauer A, Greenberg P, Negrin R, Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 1994;8(4):638-41
   PubMed Web of Science ®Google Scholar
• Padua RA, West RR. Oncogene mutation and prognosis in the myelodysplastic syndromes. Br J Haematol 2000;111(3):873-4
   PubMed Web of Science ®Google Scholar
• Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000;96(5):1655-69
   PubMed Web of Science ®Google Scholar
• Li N, Batzer A, Daly R, Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 1993;363(6424):85-8
   PubMed Web of Science ®Google Scholar
• de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 1997;14(5):623-5
   PubMed Web of Science ®Google Scholar
• Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 2006;47(1):15-31
   PubMed Web of Science ®Google Scholar
• Agrawal AG, Somani RR. Farnesyltransferase inhibitor as anticancer agent. Mini Rev Med Chem 2009;9(6):638-52
   PubMed Web of Science ®Google Scholar
• Lerner EC, Qian Y, Blaskovich MA, Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 1995;270(45):26802-6
   PubMed Web of Science ®Google Scholar
• Lerner EC, Zhang TT, Knowles DB, Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 1997;15(11):1283-8
   PubMed Web of Science ®Google Scholar
• Bolick SC, Landowski TH, Boulware D, The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 2003;17(2):451-7
   PubMed Web of Science ®Google Scholar
• Santucci R, Mackley PA, Sebti S, Alsina M. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma. Cancer Control 2003;10(5):384-7
   PubMedGoogle Scholar
• Tamanoi F. Inhibitors of Ras farnesyltransferases. Trends Biochem Sci 1993;18(9):349-53
   PubMed Web of Science ®Google Scholar
• Sebti SM, Hamilton AD. Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs. Biochem Soc Trans 1996;24(3):692-9
   PubMed Web of Science ®Google Scholar
• Norman P. Tipifarnib (Janssen Pharmaceutica). Curr Opin Investig Drugs 2002;3(2):313-9
   PubMedGoogle Scholar
• Mesa RA, Tefferi A, Gray LA, In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 2003;17(5):849-55
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Pellat-Deceunynck C, Harousseau JL, Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002;16(9):1664-7
   PubMed Web of Science ®Google Scholar
• Cortes J, Albitar M, Thomas D, Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003;101(5):1692-7
   PubMed Web of Science ®Google Scholar
• Ochiai N, Uchida R, Fuchida S, Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood 2003;102(9):3349-53
   PubMed Web of Science ®Google Scholar
• Alsina M, Fonseca R, Wilson EF, Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004;103(9):3271-7
   PubMed Web of Science ®Google Scholar
• Mor A, Dustin ML, Phillips MR, Small GTPases and LFA-1 reciprocally modulate adhesion and signaling. Immunol Rev 2007;218:114-25
   PubMed Web of Science ®Google Scholar
• End DW, Smets G, Todd AV, Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61(1):131-7
   PubMed Web of Science ®Google Scholar
• Karp JE, Lancet JE, Kaufmann SH, Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97(11):3361-9
   PubMed Web of Science ®Google Scholar
• Patnaik A, Eckhardt SG, Izbicka Z, A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clin Cancer Res 2003;9(13):4761-71
   PubMed Web of Science ®Google Scholar
• Crul M, de Klerk GJ, Smart M, Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002;20(11):2726-35
   PubMed Web of Science ®Google Scholar
• Karp JE, Flatten K, Feldman EJ, Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood 2009;113(20):4841-52
   PubMed Web of Science ®Google Scholar
• Brandwein JM, Leber BF, Howson-Jan K, A phase 1 study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with Acute Myeloid Leukemia aged 60 years and over. Leukemia 2009;23(4):631-4
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Lancet JE, Reiffers J, A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 2007;109(12):5151-6
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Martinelli G, Jadrzejczak WW, A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009;114(6):1166-73
   PubMed Web of Science ®Google Scholar
• Erba HP, Kopecky KJ, Kirschbaum MH, Phase II studies of different schedules and doses of the farnesyl transferase inhibitor tipifarnib (R115777, Zarnestra, NSC-702818) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): a North American Intergroup Study (SO432). ASH Annual Meeting Abstracts 2007;110:440
   Google Scholar
• Karp JE, Smith BD, Gojo I, Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res 2008;14(10):3077-82
   PubMed Web of Science ®Google Scholar
• Raponi M, Lancet JE, Fan H, A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008;111(5):2589-96
   PubMed Web of Science ®Google Scholar
• Gueven N, Becherel OJ, Kijas AW, Aprataxin, a novel protein that protects against genotoxic stress. Hum Mol Genet 2004;13(10):1081-93
   PubMed Web of Science ®Google Scholar
• Schellens J, Palmer P, Selfert W, A phase 1 study to determine the safety and MTD of chronic oral administration of farnesyltransferase inhibitor R115777 in patients with advanced cancer. JRF Clinical Research Reports 2001. R115777-BEL, EDMS-BEBE-2341152
   Google Scholar
• Punt C, Palmer P, Seifert W, A Phase-I study to determine the safety and maximum tolerated dose of 28 days oral administration of farnesyltransferase inhibitor R115777 in subjects with advanced cancer. JRF Clinical Research Rep Synopsis R115777-BEL-7 (terminated study), October 2000. EDMS-BEBE-1834493
   Google Scholar
• Horak I, Bowden C, Palmer P, Phase I trial to determine the safety and pharmacokinetics of R115777, a farnesyltransferase inhibitor. JRF Clinical Research Report R115777-USA-1, October 2000. EDMS-USTI-2338340
   Google Scholar
• Richards H, Thibault A, Jia X, A phase I trial to determine the safety and pharmacokinetics of 21-day dosing of a farnesyltransferase inhibitor, R115777 (ZARNESTRA™). JRF Clinical Research Report R115777-USA-3, July 2001. EDMS-USTI-2474164
   Google Scholar
• Van de Velde H, Thibault A, Hoffman K, A pilot phase 2 study of farnesyltransferase inhibitor R115777 in subjects with superficial bladder cancer. JRF Clinical Research Report R115777-USA-7, 2003. EDMS-PSDB-1500663
   Google Scholar
• Richards H, De Porre P, Thibault A, A phase 2 trial to determine the antitumor activity of farnesyltransferase inhibitor R115777 in subjects with relapsed small cell lung cancer. JRF Clinical Research Report R115777-USA-8, 2002. EDMS-PSDB-1508187
   Google Scholar
• Howes A, Michiels B, Zannikos P, An open study of the efficacy, safety and pharmacodynamics of the farnesyl protein inhibitor, R115777, in advanced breast cancer. JRF Clinical Research Report R1157777-GBR-1, September 2003, EDMS-PSDB-1675498
   Google Scholar
• Palmer P, Kerstens R, Zannikos P, A phase 2 trial of R115777, an oral farnesyltransferase inhibitor (FTI), in subjects with advanced urothelial tract transitional cell carcinoma. J&JPRD Clinical Study Report R115777-INT-10, 2003. EDMS-PSDB-2125081
   Google Scholar
• Palmer P, Thibault A, Zannikos P, A randomized, double-blind, placebo-controlled Phase 3 study of chronic oral adminstration of farnesyltransferase inhibitor R11577 plus supportive care versus supportive care alone in subjects with advanced colorectal cancer, after chemotherapy failure. J&JPRD Clinical Study report R115777-INT-9, 2003. EDMS-PSDB-1814193
   Google Scholar